PharmaCyte Biotech Statistics
Total Valuation
PMCB has a market cap or net worth of $11.43 million. The enterprise value is -$9.41 million.
Market Cap | 11.43M |
Enterprise Value | -9.41M |
Important Dates
The next estimated earnings date is Tuesday, December 31, 2024, after market close.
Earnings Date | Dec 31, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
PMCB has 6.97 million shares outstanding. The number of shares has decreased by -43.88% in one year.
Current Share Class | 6.97M |
Shares Outstanding | 6.97M |
Shares Change (YoY) | -43.88% |
Shares Change (QoQ) | -2.92% |
Owned by Insiders (%) | 2.86% |
Owned by Institutions (%) | 14.62% |
Float | 6.19M |
Valuation Ratios
The trailing PE ratio is 2.21.
PE Ratio | 2.21 |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.27 |
P/TBV Ratio | 0.27 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.47
Current Ratio | 4.47 |
Quick Ratio | 4.36 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 43.18% and return on invested capital (ROIC) is -6.44%.
Return on Equity (ROE) | 43.18% |
Return on Assets (ROA) | -5.05% |
Return on Capital (ROIC) | -6.44% |
Revenue Per Employee | n/a |
Profits Per Employee | $4.71M |
Employee Count | 2 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.07% in the last 52 weeks. The beta is -0.23, so PMCB's price volatility has been lower than the market average.
Beta (5Y) | -0.23 |
52-Week Price Change | -28.07% |
50-Day Moving Average | 1.73 |
200-Day Moving Average | 1.95 |
Relative Strength Index (RSI) | 45.24 |
Average Volume (20 Days) | 14,144 |
Short Selling Information
The latest short interest is 52,641, so 0.76% of the outstanding shares have been sold short.
Short Interest | 52,641 |
Short Previous Month | 51,871 |
Short % of Shares Out | 0.76% |
Short % of Float | 0.85% |
Short Ratio (days to cover) | 1.09 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -5.41M |
Pretax Income | -1.14M |
Net Income | 9.42M |
EBITDA | n/a |
EBIT | -5.41M |
Earnings Per Share (EPS) | $0.74 |
Balance Sheet
Cash & Cash Equivalents | 20.84M |
Total Debt | n/a |
Net Cash | 20.84M |
Net Cash Per Share | $2.99 |
Equity (Book Value) | 43.45M |
Book Value Per Share | 6.18 |
Working Capital | 16.56M |
Cash Flow
Operating Cash Flow | -1.94M |
Capital Expenditures | n/a |
Free Cash Flow | -1.94M |
FCF Per Share | -$0.28 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
PMCB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 43.88% |
Shareholder Yield | 43.88% |
Earnings Yield | 82.47% |
FCF Yield | -16.96% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 12, 2021. It was a reverse split with a ratio of 0.0006667:1.
Last Split Date | Jul 12, 2021 |
Split Type | Reverse |
Split Ratio | 0.0006667:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |